Reports and Releases
FIT Biotech Oy: FIT Biotech files a patent application for using its GTU-based technology against the Chikungunya virus
FIT Biotech Oy
Company release 04.10.2018 at 11:00 AM EET
FIT Biotech files a patent application for using its GTU-based technology against the Chikungunya virus
FIT Biotech Oy ("Company", FITBIO: FN Finland) has filed a patent application for using its proprietary GTU® platform against the Chikungunya virus (CHKV). The application supports the Company's strategy in developing antibody-based drugs against infectious disease.
CHKV is a virus that is transmitted to humans by infected mosquitoes. Currently there are no vaccines nor cures for the disease that causes fever and debilitating joint pain that can last for years. According to the World Health Organization (WHO) millions of cases in total have been reported in Africa, Asia, the Americas and the Indian subcontinent, but local infections have also been reported in Italy, Spain and France. The Company is developing a GTU®-based antibody treatment against the disease.
CEO Erkki Pekkarinen comments: "We are excited to receive such positive results from our research on the Chikungunya virus. It seems that our GTU-based technology could be opening new ways in the prevention and treatment of Chikungunya. This could also lead to a considerable improvement in the quality of life in virus infected areas."
FIT BIOTECH OY
Board of Directors
For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080
Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000